A Phase 1 interventional study of Tovorafenib in Low-grade Glioma, sponsored by Ipsen. Active, not recruiting at 6 sites in Japan. Open to participants aged 6 Months to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Ipsen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate safety and the way the body absorbs, distributes and gets rid of the study drug tovorafenib in the body in Japanese children, adolescents and young adults with specific brain tumours. This includes how the drug is absorbed, distributed and eliminated from the body (called pharmacokinetics). The study will also test how well the drug works to shrink brain tumours.
In this study, all participants will receive tovorafenib orally once weekly.
There will be four periods in this study:
Treatment period (up to 24 months): All eligible participants will receive tovorafenib.
This requires five visits for the first 2 months (Cycle 1 and Cycle 2) followed by one visit every month (at the start of each treatment cycle). Participants will receive the first oral dose of tovorafenib on Day 1 of Cycle 1 at the study clinic. After Day 1, participants will need to take tovorafenib once weekly on Day 8, Day 15 and Day 22. Participants will be required to come to the study clinic in person at least five times for Cycle 1 and Cycle 2.
In addition, participants will have one remote visit (telephone call) during Cycle 1. After Cycle 2, only one in-person clinic visit is required at the start of each treatment cycle. A participant will stop treatment if their disease gets worse, if treatment has a harmful effect, or if they do not want to take part in the study anymore.
During the study, participants will undergo various health measurements and observations, including blood sampling and urine collections. Each participant will be in this study for up to approximately 4 years. Tovorafenib will be provided to participants who tolerate it for as long as their disease does not progress.
Once tovorafenib becomes approved and commercially available in Japan, participants may transition to the commercial drug for continued treatment.
A participant may withdraw consent to participate at any time.
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablet or powder for reconstitution / powder for oral suspension, administred once weekly
Drug: Tovorafenib
Tablet or powder for reconstitution / powder for oral suspension
Also known as: Ojemda®
Percentage of participants experiencing Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)
Time frame: From first dose until 30 days post-treatment
Percentage of participants experiencing Serious Adverse Events (SAEs) and AESIs
An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention.
Time frame: Up to 4 years from first dose, including post-treatment monitoring
Area under the plasma concentration-time curve from time zero to last measurable concentration (AUC₀-t) of tovorafenib following a single dose
AUC₀-t represents the total drug exposure over time from administration until the last measurable concentration after a single dose of tovorafenib.
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC₀-inf) of tovorafenib following a single dose
AUC₀-inf estimates the total drug exposure from administration to infinite time, extrapolating beyond the last measurable concentration.
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Maximum observed plasma concentration (Cmax) of tovorafenib following a single dose
Cmax is the highest concentration of tovorafenib observed in plasma after a single dose
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Time to maximum plasma concentration following a single dose (Tmax) of tovorafenib
Tmax refers to the time point at which the maximum observed plasma concentration of tovorafenib is reached following a single dose
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Terminal half-life (t½) of tovorafenib following a single dose
Terminal half-life (t½) will be assessed following a single dose of tovorafenib.
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Area under the plasma concentration-time curve over the dosing interval at steady-state (AUC₀-tau) of tovorafenib
AUC₀-tau refers to the area under the plasma concentration-time curve over the dosing interval (tau) during steady-state conditions, representing total drug exposure per dosing cycle
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Maximum plasma concentration at steady-state (CmaxSS) of tovorafenib
CmaxSS refers to the maximum observed plasma concentration of tovorafenib measured during steady-state conditions, after repeated dosing when drug input and elimination have reached equilibrium.
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Minimum plasma concentration at steady-state (CminSS) of tovorafenib
CminSS refers to the lowest observed plasma concentration of tovorafenib during steady-state conditions, reflecting trough levels between doses.
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Average Plasma Concentration at Steady-State (CavSS) of tovorafenib
CavSS refers to the average plasma concentration of tovorafenib over the dosing interval during steady-state conditions, calculated from multiple time points
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Time to maximum plasma concentration at steady-state (TmaxSS) of tovorafenib
TmaxSS refers to the time point at which the maximum plasma concentration of tovorafenib is observed during steady-state conditions
Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)
Change in total tumor volume over time
Assessment based on MRI imaging data to evaluate tumor volume and its evolution during treatment.
Time frame: Every 12 weeks from Cycle 1 Day 1 up to end of treatment (approximately 24 months).
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jul 2030, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tovorafenib